AstraZeneca ’s faslodex receives EU approval for advanced breast cancer treatment
The European Commission (EC) has approved AstraZeneca ’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Pharmaceuticals | Women